RxDoctor Payments Data

Roderick Haithcock, MD

Internal Medicine · Richmond, VANPI 1801884580

Payments from drug & device makers

$3,586in general payments, 2019–2025

Across 207 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$345
  • Abbott$313
  • AbbVie$270
  • Bayer$246
  • Sanofi-aventis U.S. LLC$219
  • Novartis$191
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,48797%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,586 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$142,937
Medicare patients
304
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol251$258,166
JardianceEmpagliflozin198$202,603
MounjaroTirzepatide162$182,915
TrulicityDulaglutide92$101,758
EliquisApixaban147$100,168
OzempicSemaglutide61$70,501
JanuviaSitagliptin Phosphate58$68,051
EntrestoSacubitril/Valsartan50$41,814
XareltoRivaroxaban35$40,488
MyrbetriqMirabegron36$25,917
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$20,504
TradjentaLinagliptin33$19,697
SymbicortBudesonide/Formoterol Fumarate40$17,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,804
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp24$15,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$162$289,381288 claims
AstraZenecaFarxiga, Symbicort, Brilinta$129$283,642305 claims
Boehringer IngelheimJardiance, Tradjenta$20$222,301231 claims
PfizerEliquis$47$100,168147 claims
Novo NordiskOzempic$345$70,50161 claims
MerckJanuvia$41$68,05158 claims
NovartisEntresto$191$41,81450 claims
Johnson & JohnsonXarelto$68$40,48835 claims
GSKTrelegy Ellipta, Breo Ellipta$42$30,19443 claims
Astellas Pharma US IncMyrbetriq$160$25,91736 claims
AbbVieLinzess$270$8,21614 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$12$5,98412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →